About US
Contact us
-
Eli Lilly's Medicaid rebate payments under fire as whistleblower lawsuit heads to trialEli Lilly is headed to trial over claims it skimped on Medicaid rebate payments. U.S. District Judge Harry Leinenweber has shot down Lilly’s motion to end a 2014 whistleblower lawsuit, concludi2022/3/2
-
With Bayer's new launches in infancy, Eylea and Xarelto still rule its pharma business—but for how long?Bayer is gradually shifting its pharma focus to a group of new blockbuster candidates and novel platforms. But before those drugs realize their potential, eye med Eylea and blood thinner Xarelto rema2022/3/2
-
Gilead's HIV prospect lenacapavir hits FDA approval snag amid vial compatibility concernsAfter a quality glitchscuppered multiple trials of an investigational HIV drug late last year, Gilead Sciences vowed to sort out the problem swiftly. Now, the drug also faces a hurdle on its path to2022/2/28
-
FibroGen’s roxadustat safety mess draws SEC scrutiny as AstraZeneca-partnered anemia drug remains in limboFibroGen and partner AstraZeneca have yet to figure out an FDA path for their once-rejected anemia drug roxadustat. And now, another regulator is piling into the mess. FibroGen received a subpo2022/2/28
-
Johnson & Johnson, Moderna set to face shareholder votes on vaccine pricing strategy, manufacturing tech sharingThroughout the global push to produce COVID-19 vaccines, pharma companies have frequently come under fire for unequal access to their shots. Oxfam, in a bid to force better access, has scored a pair2022/2/24
-
AbbVie advances major depressive disorder ambitions for Vraylar with hopes for $4B-plus in salesAbbVie’s Allergan-acquired antipsychotic medicine Vraylar is alreadygoing gangbusters in its twoapproved indications. An expansion into tough-to-treat depression, meanwhile, would only build on the m2022/2/24
-
Moderna taps Thermo Fisher for 15-year mRNA production pact for COVID vaccines and moreIn the third year of the pandemic, mRNA specialist Moderna is marshaling one of its tried-and-true manufacturing partners to lock up production of its COVID shot for years to come. Modern2022/2/22
-
Biohaven lines up rhinosinusitis patients for trial of its migraine med Nurtec ODTEven in a crowded field full of formidable competitors, Biohaven has set itself apart with migraine medication Nurtec ODT just two years after it was approved. Now the company has another2022/2/22
-
ASCO GU: J&J plays up precision therapy approach for Zejula's prostate cancer bid after mixed resultsIn 2017 and 2020, Zejula snagged broad FDA labels for ovarian cancer patients who responded well to a chemotherapy. But in prostate cancer, the PARP inhibitor appears to work only for a niche populat2022/2/16
-
ASCO GU: AstraZeneca, Merck’s Lynparza one-ups J&J’s Zejula with prostate cancer win regardless of gene mutationsAstraZeneca and Merck & Co.’s Lynparza may have a narrower label than GlaxoSmithKline’s rival drug Zejula in ovarian cancer, but in prostate cancer, the situation could flip. Adding L2022/2/16